Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14110914 | 1.00 | PRKCQ (0.30) | PRKCQPRKCD | |
| SCHEMBL930081 | 1.00 | PRKCQ (0.30) | PRKCQPRKCD | |
| Hydrochloric Acid SCHEMBL27829628 | 0.98 | — | — | |
| SCHEMBL20161408 | 0.87 | ROCK2 (0.34) | — | |
| SCHEMBL30613297 | 0.83 | — | — | |
| SCHEMBL23981028 | 0.80 | — | — | |
| SCHEMBL2760247 | 0.80 | — | — | |
| SCHEMBL2741655 | 0.80 | NCF1 (0.32) | — | |
| SCHEMBL21318183 | 0.76 | — | — | |
| SCHEMBL24456790 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240300927-A1 | AMIDES AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4426691-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | Genentech, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118201921-A | Lactams as CBL-B inhibitors selective for C-CBL | 基因泰克公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024077236-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4288429-A1 | LACTAMS AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009144201-A1 | IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-12-03 | — | — | WO | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | PRKCQ 368/4885PRKCD 596/4885 |
| US-20240300927-A1 | AMIDES AS CBL-B INHIBITORS | CBLB, CBL, CBLC | PRKCQ 235/4885PRKCD 436/4885 |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | PRKCQ 306/4885PRKCD 385/4885 |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | FLT4, UACA, FLT1 | PRKCQ 3085/4885PRKCD 3261/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PRKCQ 4143/4885PRKCD 3404/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PRKCQ 3644/4885PRKCD 3968/4885 |
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | CBL, CBLB, CBLC | PRKCQ 413/4885PRKCD 308/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | PRKCQ 2102/4885PRKCD 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.